Istradefylline for the treatment of Parkinson's disease

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study

(2010) Yoshikuni Mizuno et al.   MOVEMENT DISORDERS

A long-term study of istradefylline in subjects with fluctuating Parkinson's disease

(2010) Stewart Factor et al.   PARKINSONISM & RELATED DISORDERS

A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease

(2009) C. Warren Olanow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial

(2009) H.H. Fernandez et al.   PARKINSONISM & RELATED DISORDERS

Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)

(2008) Peter A. LeWitt et al.   ANNALS OF NEUROLOGY

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

(2008) Robert A. Hauser et al.   MOVEMENT DISORDERS

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

(2008) M. Stacy et al.   NEUROLOGY